Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009

Peritoneal Cancer ◽

Southwest Oncology Group Study

A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q)

Yearbook of Oncology ◽

10.1016/j.yonc.2011.07.016 ◽

2011 ◽

Vol 2011 ◽

pp. 74-75

Author(s):

J.T. Thigpen

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

Platinum Sensitive

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.10.001 ◽

2018 ◽

Vol 151 (3) ◽

pp. 422-427 ◽

Cited By ~ 7

Author(s):

Bradley J. Monk ◽

James T. Kauderer ◽

Katherine M. Moxley ◽

Albert J. Bonebrake ◽

Summer B. Dewdney ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Gynecologic Oncology ◽

Weekly Paclitaxel ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

Platinum Resistant

A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q)

Yearbook of Medicine ◽

10.1016/s0084-3873(11)00207-0 ◽

2011 ◽

Vol 2011 ◽

pp. 154-155

Author(s):

J.T. Thigpen

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

Platinum Sensitive

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.03.042 ◽

2015 ◽

Vol 137 (3) ◽

pp. 386-391 ◽

Cited By ~ 146

Author(s):

Robert L. Coleman ◽

Michael W. Sill ◽

Katherine Bell-McGuinn ◽

Carol Aghajanian ◽

Heidi J. Gray ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Parp Inhibitor ◽

Brca2 Mutation ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.03.036 ◽

2011 ◽

Vol 122 (1) ◽

pp. 111-115 ◽

Cited By ~ 57

Author(s):

Robert L. Coleman ◽

William E. Brady ◽

D. Scott McMeekin ◽

Peter G. Rose ◽

John T. Soper ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

Platinum Resistant

A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.12.008 ◽

2019 ◽

Vol 152 (3) ◽

pp. 548-553 ◽

Cited By ~ 4

Author(s):

Ursula A. Matulonis ◽

Michael W. Sill ◽

Vicky Makker ◽

David G. Mutch ◽

Jay W. Carlson ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

Randomized Phase Ii

A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG–PEI–cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2014.03.571 ◽

2014 ◽

Vol 133 (3) ◽

pp. 433-438 ◽

Cited By ~ 44

Author(s):

Ronald D. Alvarez ◽

Michael W. Sill ◽

Susan A. Davidson ◽

Carolyn Y. Muller ◽

David P. Bender ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – a Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2014.03.156 ◽

2014 ◽

Vol 133 ◽

pp. 56-57 ◽

Cited By ~ 7

Author(s):

R.L. Coleman ◽

M. Sill ◽

C. Aghajanian ◽

H.J. Gray ◽

K.S. Tewari ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Parp Inhibitor ◽

Brca2 Mutation ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q)

Gynecologic Oncology ◽

10.1016/j.ygyno.2010.11.008 ◽

2011 ◽

Vol 120 (3) ◽

pp. 454-458 ◽

Cited By ~ 21

Author(s):

Thomas J. Herzog ◽

Michael W. Sill ◽

Joan L. Walker ◽

David O'Malley ◽

Mark Shahin ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

Platinum Sensitive

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – a Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2013.04.465 ◽

2013 ◽

Vol 130 (1) ◽

pp. e168 ◽

Cited By ~ 3

Author(s):

R. Coleman ◽

M. Sill ◽

C. Aghajanian ◽

H. Gray ◽

K. Tewari ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Parp Inhibitor ◽

Brca2 Mutation ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽